Hunan Nucien Pharmaceutical, founded in December 2006, is an innovative pharmaceutical company focusing on the R & D, manufacturing and marketing of small molecule medicines. At present, the company has 34 product lines, 53 drug registration approvals and 8 API registration approvals, including 3 exclusive products and 9 exclusive dosage forms or specifications. Its main products include antivirals、cardiovascular drugs、antibiotics and other products. The company's class 1.1 innovative drug, peramivir sodium chloride injection, has been recognized by the market after several years of marketing, and now enjoys a strong competitive edge for the treatment of influenza.
|Full name||Hunan Nucien Pharmaceutical Co., Ltd.|
|Domicile||No.1 Kangli Road, Liuyang Economic and Technological Development Zone, Changsha, Hunan.|
|Has weighted voting rights structure?||No|
|Earnings Per Share||0.46||0.12||0.04|
|R&D expenditure as a % of operating revenue||6.46%||6.35%||5.93%|
|Total Owners' Equity||234.30||180.78||153.63|
|Net Cash Flows-Operating||64.41||70.72||75.35|
|Net Cash Flows-Investing||-21.18||-46.49||-28.48|
|Net Cash Flows-Financing||6.89||-52.71||10.15|
|Name||No. of Shares Held (mn)||% of Shares Held|
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.